Management of Symptomatic Intracranial Stenosis

David A. Hoak, Helmi Lutsep

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Intracranial atherosclerotic disease is a common cause of stroke worldwide, causing approximately 10 % of strokes in the USA and up to 50 % in Asian populations. Recurrent stroke risks are particularly high in those with a stenosis of 70 % or more and a recent transient ischemic attack or stroke. Warfarin has been associated with higher major hemorrhage rates and no reduction of recurrent stroke compared to aspirin in patients with symptomatic intracranial stenosis. After early trials showed the feasibility of stenting, two randomized trials compared stenting plus medical management to medical management alone in symptomatic intracranial stenosis. Stenting was linked with increased risk and showed no benefit in any subpopulation of patients. Aggressive medical management in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was associated with half the risk of stroke compared to that in similar patients in a previous symptomatic intracranial stenosis trial after adjustment of confounding characteristics. Aggressive medical management comprises risk factor control, including a target systolic blood pressure <140 mmHg, a low density lipoprotein <70 mg/dL, hemoglobin A1C <7.0 %, and lifestyle management that incorporates exercise, smoking cessation and weight management, and the use of antithrombotics.

Original languageEnglish (US)
Article number83
JournalCurrent Cardiology Reports
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Pathologic Constriction
Stroke
Blood Pressure
Social Adjustment
Transient Ischemic Attack
Smoking Cessation
Warfarin
LDL Lipoproteins
Aspirin
Life Style
Hemoglobins
Exercise
Hemorrhage
Weights and Measures
Population

Keywords

  • Intracranial stenosis
  • Ischemic stroke
  • Medical management
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Management of Symptomatic Intracranial Stenosis. / Hoak, David A.; Lutsep, Helmi.

In: Current Cardiology Reports, Vol. 18, No. 9, 83, 01.09.2016.

Research output: Contribution to journalReview article

@article{165871f00bc243b4b1720048b2f0f416,
title = "Management of Symptomatic Intracranial Stenosis",
abstract = "Intracranial atherosclerotic disease is a common cause of stroke worldwide, causing approximately 10 {\%} of strokes in the USA and up to 50 {\%} in Asian populations. Recurrent stroke risks are particularly high in those with a stenosis of 70 {\%} or more and a recent transient ischemic attack or stroke. Warfarin has been associated with higher major hemorrhage rates and no reduction of recurrent stroke compared to aspirin in patients with symptomatic intracranial stenosis. After early trials showed the feasibility of stenting, two randomized trials compared stenting plus medical management to medical management alone in symptomatic intracranial stenosis. Stenting was linked with increased risk and showed no benefit in any subpopulation of patients. Aggressive medical management in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was associated with half the risk of stroke compared to that in similar patients in a previous symptomatic intracranial stenosis trial after adjustment of confounding characteristics. Aggressive medical management comprises risk factor control, including a target systolic blood pressure <140 mmHg, a low density lipoprotein <70 mg/dL, hemoglobin A1C <7.0 {\%}, and lifestyle management that incorporates exercise, smoking cessation and weight management, and the use of antithrombotics.",
keywords = "Intracranial stenosis, Ischemic stroke, Medical management, Stroke",
author = "Hoak, {David A.} and Helmi Lutsep",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s11886-016-0762-5",
language = "English (US)",
volume = "18",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - Management of Symptomatic Intracranial Stenosis

AU - Hoak, David A.

AU - Lutsep, Helmi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Intracranial atherosclerotic disease is a common cause of stroke worldwide, causing approximately 10 % of strokes in the USA and up to 50 % in Asian populations. Recurrent stroke risks are particularly high in those with a stenosis of 70 % or more and a recent transient ischemic attack or stroke. Warfarin has been associated with higher major hemorrhage rates and no reduction of recurrent stroke compared to aspirin in patients with symptomatic intracranial stenosis. After early trials showed the feasibility of stenting, two randomized trials compared stenting plus medical management to medical management alone in symptomatic intracranial stenosis. Stenting was linked with increased risk and showed no benefit in any subpopulation of patients. Aggressive medical management in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was associated with half the risk of stroke compared to that in similar patients in a previous symptomatic intracranial stenosis trial after adjustment of confounding characteristics. Aggressive medical management comprises risk factor control, including a target systolic blood pressure <140 mmHg, a low density lipoprotein <70 mg/dL, hemoglobin A1C <7.0 %, and lifestyle management that incorporates exercise, smoking cessation and weight management, and the use of antithrombotics.

AB - Intracranial atherosclerotic disease is a common cause of stroke worldwide, causing approximately 10 % of strokes in the USA and up to 50 % in Asian populations. Recurrent stroke risks are particularly high in those with a stenosis of 70 % or more and a recent transient ischemic attack or stroke. Warfarin has been associated with higher major hemorrhage rates and no reduction of recurrent stroke compared to aspirin in patients with symptomatic intracranial stenosis. After early trials showed the feasibility of stenting, two randomized trials compared stenting plus medical management to medical management alone in symptomatic intracranial stenosis. Stenting was linked with increased risk and showed no benefit in any subpopulation of patients. Aggressive medical management in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was associated with half the risk of stroke compared to that in similar patients in a previous symptomatic intracranial stenosis trial after adjustment of confounding characteristics. Aggressive medical management comprises risk factor control, including a target systolic blood pressure <140 mmHg, a low density lipoprotein <70 mg/dL, hemoglobin A1C <7.0 %, and lifestyle management that incorporates exercise, smoking cessation and weight management, and the use of antithrombotics.

KW - Intracranial stenosis

KW - Ischemic stroke

KW - Medical management

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84983085344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983085344&partnerID=8YFLogxK

U2 - 10.1007/s11886-016-0762-5

DO - 10.1007/s11886-016-0762-5

M3 - Review article

C2 - 27443379

AN - SCOPUS:84983085344

VL - 18

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 9

M1 - 83

ER -